|
|
|
|
| Symbol(s): |
QLTI |
| Date: |
24-May-13 |
| Author: |
Hunter Orr |
| Contributor: |
Alpha Street Research |
| Title: |
QLTI - QLT Inc - Upgraded to a Buy - Company Analysis and ASR Ranking Report |
| Document Size: |
9 pages |
| Price: |
$24 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $24. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The Company's lead drug, Visudyne, is marketed by Novartis AG, and is used in the treatment of the wet form of age-related macular degeneration.
| | |
|
|
